IMV

IMV Inc. [IMV] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

IMV Stock Summary

In the News

11:02 29 Mar 2024 IMV

IMV Inc. (IMV) Q4 2022 Earnings Call Transcript

IMV Inc. (NASDAQ:IMV ) Q4 2022 Earnings Conference Call March 16, 2023 8:00 AM ET Company Participants Andrew Hall - Chief Executive Officer Brittany Davison - Chief Accounting Officer Jeremy Graff - Chief Scientific Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Brandon Folkes - Cantor Fitzgerald Doug Loe - Leede Jones Gable Operator Good day and thank you for standing by.

07:05 29 Mar 2024 IMV

IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company's 2022 fourth quarter and fiscal year-end financial and operational results.

09:25 29 Mar 2024 IMV

IMV, Inc. (IMV) Q3 2022 Earnings Call Transcript

IMV, Inc. (NASDAQ:IMV ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Brittany Davison - Chief Accounting Officer Andrew Hall - Chief Executive Officer Jeremy Graff - Chief Scientific Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Joseph Pantginis - H.C. Wainwright & Co. Paul Stewardson - IA Capital Markets Operator Good day and thank you for standing by.

07:05 29 Mar 2024 IMV

IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.

07:05 29 Mar 2024 IMV

IMV Inc. to Present at Two Investor Conferences in September

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that members of IMV's executive management team will be presenting at two investor conferences in September. Please find additional details on the conferences below. H.C. Wainwright 24th Annual Global Investment Conference, New York City

02:17 29 Mar 2024 IMV

IMV Inc. (IMV) CEO Andrew Hall on Q2 2022 Results - Earnings Call Transcript

IMV Inc. (NASDAQ:IMV ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Brittany Davison - Senior Vice President of Finance Andrew Hall - Chief Executive Officer Jeremy Graff - Chief Medical Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the IMV Second Quarter 2022 Earnings Call.

07:05 29 Mar 2024 IMV

IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, August 11, 2022, at 8:00 a.m. ET to discuss the company's 2022 second quarter financial and operational results. Financial analysts are invited to join

08:05 29 Mar 2024 IMV

IMV Inc. to Present at the H.C. Wainwright Global Investment Conference

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that members of IMV's executive management team will be participating in person at the H.C. Wainwright Global Investment Conference, which will be held in person and virtually May 23-26, 2022 in Miami, FL. H.C. Wainwright Global Investmen

12:13 29 Mar 2024 IMV

IMV Inc. (IMV) CEO Andrew Hall on Q1 2022 Results - Earnings Call Transcript

IMV Inc. (NASDAQ:IMV ) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Andrew Hall – Chief Executive Officer Jeremy Graff – Chief Medical Officer Brittany Davison – Senior Vice President, Finance Joy Bessenger – Senior Vice President, Investor Relations & Corporate Strategy Conference Call Participants Joseph Pantginis – H.C. Wainwright & Co. Nick Abbott – Wells Fargo Securities Brandon Folkes – Cantor Fitzgerald Paul Stewardson – iA Capital Markets Joy Bessenger Good morning, everyone.

07:05 29 Mar 2024 IMV

IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, May 13, 2022, at 8:00 a.m. ET to discuss the company's 2022 first quarter financial and operational results. Financial analysts are invited to join the con

IMV Financial details

Company Rating
Sell
Market Cap
9.63M
Income
-36.62M
Revenue
0
Book val./share
-0.01
Cash/share
0.03
Dividend
-
Dividend %
-
Employees
63
Optionable
No
Shortable
Yes
Earnings
09 Aug 2023
P/E
-18.5
Forward P/E
-
PEG
5.73
P/S
-
P/B
-102.6
P/C
-
P/FCF
-0.28
Quick Ratio
2.46
Current Ratio
2.93
Debt / Equity
-4.38
LT Debt / Equity
-4.32
-
-
EPS (TTM)
-3.42
EPS next Y
-
EPS next Q
-
EPS this Y
-8.71%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
3.35%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-98.84%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
152.88%
Inst Trans
1.36%
ROA
-117%
ROE
-12237%
ROC
-1.75%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
11.71M
Shs Float
10.17M
-
-
-
-
Target Price
-
52W Range
2.0E-4-10.4
52W High
-
52W Low
-
RSI
-
Rel Volume
0.29
Avg Volume
152.41K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.52236
-
-
Volatility
0.33%, 0.33%
Prev Close
-
Price
-
Change
-

IMV Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.010.01000
Net income per share
-3.91-4.410-5.05-4.61
Operating cash flow per share
-2.88-4.210-4.32-4
Free cash flow per share
-3.25-4.280-4.51-4.13
Cash per share
2.52.1705.22.54
Book value per share
0.720.9902.9-0.79
Tangible book value per share
0.720.9902.9-0.79
Share holders equity per share
0.720.9902.9-0.79
Interest debt per share
1.831.702.773.52
Market cap
308.23M188.07M090.52M20.27M
Enterprise value
304.31M184.78M-28.37M71.56M27.95M
P/E ratio
-18-8.590-2.41-0.53
Price to sales ratio
5.12K4.16K000
POCF ratio
-24.44-90-2.82-0.61
PFCF ratio
-21.68-8.850-2.71-0.59
P/B Ratio
97.2538.104.2-3.07
PTB ratio
97.2538.104.2-3.07
EV to sales
5.05K4.09K-12.06K00
Enterprise value over EBITDA
-20.49-9.431.05-2.04-0.73
EV to operating cash flow
-24.13-8.851.04-2.23-0.84
EV to free cash flow
-21.41-8.691.03-2.14-0.81
Earnings yield
-0.06-0.120-0.41-1.9
Free cash flow yield
-0.05-0.110-0.37-1.7
Debt to equity
2.211.520.260.91-4.38
Debt to assets
0.420.440.170.390.92
Net debt to EBITDA
0.260.171.050.54-0.2
Current ratio
2.573.065.345.012.93
Interest coverage
-14.84-21.09-967.22-39.34-78.83
Income quality
0.78110.880.88
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
112.72171.875.07K00
Research and developement to revenue
156.73321.88.87K00
Intangibles to total assets
00000
Capex to operating cash flow
0.130.020.010.040.03
Capex to revenue
-26.65-8.07-147.3300
Capex to depreciation
-6.72-0.9-0.86-2.59-1.07
Stock based compensation to revenue
20.6116.0551400
Graham number
7.989.93018.179.06
ROIC
-1.43-1.56-0.68-0.85-1.69
Return on tangible assets
-1.02-1.28-0.59-0.75-1.23
Graham Net
-0.31-0.0101.53-1.83
Working capital
8.99M10.1M35.67M37.13M18.17M
Tangible asset value
3.17M4.94M30.88M21.54M-6.6M
Net current asset value
1.05M2.77M28.65M17.81M-10.36M
Invested capital
2.211.520.260.91-4.38
Average receivables
1.19M1.86M2.51M2.42M1.83M
Average payables
2.61M3.34M3.27M4.18M3.91M
Average inventory
0.50.5000
Days sales outstanding
10.9K15.5K481.07K00
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.030.02000
Payables turnover
00000
Inventory turnover
00000
ROE
-5.4-4.44-0.89-1.745.83
Capex per share
-0.37-0.070-0.19-0.13

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-12-312022-03-312022-06-302022-09-30 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1.65-1.32-1.19-0.9-0.01
Operating cash flow per share
-1-1.21-0.84-1.24-0.01
Free cash flow per share
-1.09-1.22-0.91-1.27-0.01
Cash per share
5.23.493.782.640.03
Book value per share
2.91.420.29-0.77-0.01
Tangible book value per share
2.91.420.29-0.77-0.01
Share holders equity per share
2.91.420.29-0.77-0.01
Interest debt per share
2.712.463.623.590.04
Market cap
90.52M115.91M53.87M43.03M2B
Enterprise value
71.56M107.18M52.46M50.1M2.01B
P/E ratio
-1.85-2.68-1.38-1.45-58.24
Price to sales ratio
00000
POCF ratio
-12.19-11.63-7.78-4.21-317.62
PFCF ratio
-11.23-11.59-7.16-4.12-307.51
P/B Ratio
4.29.9122.31-6.81-303.14
PTB ratio
4.29.9122.31-6.81-303.14
EV to sales
00000
Enterprise value over EBITDA
-6.47-10.67-5.37-5.33-242.98
EV to operating cash flow
-9.64-10.76-7.58-4.91-318.83
EV to free cash flow
-8.88-10.72-6.97-4.8-308.69
Earnings yield
-0.13-0.09-0.18-0.170
Free cash flow yield
-0.09-0.09-0.14-0.240
Debt to equity
0.911.7112.31-4.56-4.38
Debt to assets
0.390.490.730.890.92
Net debt to EBITDA
1.720.870.14-0.75-0.93
Current ratio
5.013.854.192.82.93
Interest coverage
-23.92-33.62-138.6-12.96226.05
Income quality
0.630.950.71.140.73
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.0900.090.020.03
Capex to revenue
00000
Capex to depreciation
-3.04-0.18-2.77-0.8-0.64
Stock based compensation to revenue
00000
Graham number
10.376.492.83.950.04
ROIC
-0.27-0.32-0.29-0.34-0.36
Return on tangible assets
-0.24-0.27-0.24-0.23-0.27
Graham Net
1.530.17-0.67-1.88-0.02
Working capital
37.13M27.13M27.75M18.25M18.17M
Tangible asset value
21.54M11.7M2.42M-6.32M-6.6M
Net current asset value
17.81M7.53M-1.63M-10.22M-10.36M
Invested capital
0.911.7112.31-4.56-4.38
Average receivables
1.8M2.09M2.19M1.86M1.85M
Average payables
2.31M2.31M001.59M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.57-0.93-4.041.181.3
Capex per share
-0.090-0.07-0.030

IMV Frequently Asked Questions

What is IMV Inc. stock symbol ?

IMV Inc. is a CA stock , located in Dartmouth of Ns and trading under the symbol IMV

What is IMV Inc. stock quote today ?

IMV Inc. stock price is $- today.

Is IMV Inc. stock public?

Yes, IMV Inc. is a publicly traded company.

Something similar

Top by Market Cap
Similar Market Cap